Evidence map›Paper›PMID 25123143›Full record

ReviewWiener klinische Wochenschrift2014

Auditory hallucinations associated with nitrofurantoin use: case report and review of the literature.

Matej Štuhec

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Wiener klinische Wochenschrift, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Matej ŠtuhecDepartment for Clinical Pharmacy, Psychiatric Hospital Ormoz, Ptujska Cesta 33, Ormoz, Slovenia, matejstuhec@gmail.com.
University Psychiatric Hospital · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn this case report, we present an 83-year-old Caucasian immune-competent woman with Alzheimer's disease and organic personality disorder who developed auditory hallucinations when treated with two nitrofurantoin (NF) tablets (100 mg) every 12 h because of acute cystitis due to extended-spectrum-β-lactamase-positive Escherichia coli. An 83-year-old Caucasian woman with Alzheimer's disease developed auditory hallucinations 2 days after intake of two NF tablets (100 mg) daily. After thorough discussion, it was decided not to rechallenge with NF because of the serious adverse effect. After NF discontinuation suggested by clinical pharmacist and switching to imipenem 500 mg and cilastatin 500 mg three times daily for 7 days, symptoms significantly improved the next day. No other drugs known to interact with NF were administered. DISCUSSION: NF-induced adverse effects have been reported frequently, but NF-induced auditory hallucinations with early onset in an immune-competent geriatric patient, without previous reported hallucinations or seizures, have not been reported in the literature. Scoring according to the Naranjo adverse drug reaction scale revealed a probable relationship between auditory hallucinations and NF use in our patient (6 points). The exact mechanism for the central nervous system (CNS) toxicity of NF in this patient is not known, but we believe that the CNS penetration of NF may result in the accumulation of toxic drug levels in CNS.

conclusionThis case report can be used to remind clinicians and clinical pharmacists of keeping in mind the potential of NF associated with auditory hallucinations, which can be easily confused with more serious conditions.

Indexed as

AgedAlzheimer DiseaseFemaleHallucinationsHumansNitrofurantoinTreatment OutcomeNitrofurantoin

Identifiers

PMID25123143
OpenAlexW121936117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.